World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
118
Citations
59833
World Ranking
4016
National Ranking
222

Research.com Recognitions

  • 1995 - Member of Academia Europaea

Overview

Volker Diehl is affiliated with the University of Cologne in Germany and focuses primarily on medical research with a particular emphasis on lymphoma.

Their research spans multiple fields of study, including:

  • Medicine

Within these broad fields, more specific subfields include:

  • Pathology and Forensic Medicine
  • Pulmonary and Respiratory Medicine
  • Radiology, Nuclear Medicine and Imaging
  • Oncology
  • Neurology

The main topics addressed in their research cover:

  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Medical Imaging Techniques and Applications
  • CNS Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Genetic factors in colorectal cancer
  • Cancer survivorship and care

Volker Diehl has published extensively in several venues, regularly appearing in:

  • The Lancet Haematology
  • Journal of Clinical Oncology
  • Hematological Oncology
  • Blood
  • British Journal of Haematology

Frequent collaborators include:

  • Peter Borchmann
  • Michael Fuchs
  • Carsten Kobe
  • Richard Greil
  • Julia Meißner

Recent published papers feature the following works:

  • PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial (2021, The Lancet Oncology)
  • PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial (2021, The Lancet Haematology)
  • Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group (2020, Journal of Clinical Oncology)
  • BRECADD IS NON-INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL (2023, Hematological Oncology)
  • Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14) (2021, The Lancet Haematology)

Volker Diehl has been recognized as a member of Academia Europaea since 1995.

Best Publications

  • Revised response criteria for malignant lymphoma

    Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne

  • Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis.

    Gertrude Henle;Werner Henle;Volker Diehl

  • Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

    Norbert Schmitz;Beate Pfistner;Michael Sextro;Markus Sieber

  • Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

    B. Coiffier;C. Haioun;N. Ketterer;A. Engert

  • Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells

    Ulrich Schwab;Harald Stein;Johannes Gerdes;Hilmar Lemke

  • Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

    Volker Diehl;Jeremy Franklin;Michael Pfreundschuh;Bernd Lathan

  • Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

    Andreas Engert;Annette Plütschow;Hans Theodor Eich;Andreas Lohri

  • Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

    U. Winkler;M. Jensen;O. Manzke;H. Schulz

  • Herpes-Type Virus and Chromosome Marker in Normal Leukocytes after Growth with Irradiated Burkitt Cells

    Werner Henle;Volker Diehl;Gertrude Kohn;Harald zur Hausen

  • Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova

  • Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma.

    Lutz Gissmann;V. Diehl;H. Schultz-Coulon;H. Zur Hausen

  • Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study

    Andreas Engert;Volker Diehl;Jeremy Franklin;Andreas Lohri

  • Antibodies to Epstein-Barr Virus in Burkitt's Lymphoma and Control Groups

    Gertrude Henle;Werner Henle;Peter Clifford;Volker Diehl

  • Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group

    Andreas Engert;Petra Schiller;Andreas Josting;Richard Herrmann

  • Antibodies to Epstein-Barr Virus in Nasopharyngeal Carcinoma, Other Head and Neck Neoplasms, and Control Groups

    Werner Henle;Gertrude Henle;Hung-Chiu Ho;Pierre Burtin

  • Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population

    Harald Stein;Johannes Gerdes;Ulrich Schwab;Hilmar Lemke

  • Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

    Hans Theodor Eich;Volker Diehl;Helen Görgen;Thomas Pabst

  • European Code Against Cancer and scientific justification: third version (2003)

    P. Boyle;P. Autier;H. Bartelink;J. Baselga

  • Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

    Ines Schwering;Andreas Bräuninger;Ulf Klein;Berit Jungnickel

  • Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

    Hendrik Pels;Ingo G.H. Schmidt-Wolf;Axel Glasmacher;Holger Schulz

Frequent Co-Authors

Andreas Engert
Andreas Engert University of Cologne
Jürgen Wolf
Jürgen Wolf University of Cologne
Gerd Fätkenheuer
Gerd Fätkenheuer University of Cologne
Richard Greil
Richard Greil Paracelsus Medical University
Harald Stein
Harald Stein Charité - University Medicine Berlin
Michael Pfreundschuh
Michael Pfreundschuh Saarland University
Markus Loeffler
Markus Loeffler Leipzig University
Andreas Hombach
Andreas Hombach University of Cologne
Hinrich Abken
Hinrich Abken University of Regensburg
Ralf Küppers
Ralf Küppers University of Duisburg-Essen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While traditional medical degrees can be demanding and expensive, a range of online options offer more flexible and affordable ways to start or advance your healthcare career. If you have an interest in the technology side of medicine, you may want to explore a health information management degree online. This pathway is ideal for those who want to manage and analyze healthcare data without direct patient care.

For students looking for quick entry into the healthcare workforce, cheapest medical billing and coding online courses are a popular choice. These courses provide foundational training in a high-demand field, often allowing you to complete your education at your own pace.

Aspiring nurses have more opportunities than ever to earn their credentials virtually. You can find most affordable online nurse practitioner programs for advanced practice roles, or choose from a range of affordable nursing programs online to start your nursing career.

These online learning pathways can help you build a strong foundation in healthcare, open diverse career options, and offer cost-effective alternatives to traditional medical education.

Best Scientists Citing Volker Diehl

Trending Scientists

Recently Published Articles